A Comparative Analysis of Endoscopic Sinus Surgery Versus Biologics for Treatment of Chronic Rhinosinusitis with Nasal Polyposis

ConclusionsAt 24-weeks and 52-weeks, ESS offers comparable SNOT-22 improvements compared to dupilumab. ESS and dupilumab offer comparable improvement in smell identification at 24-weeks. Compared to omalizumab, ESS offers superior SNOT-22 improvements. ESS offers significantly greater reductions in polyp size compared to omalizumab, dupilumab, and mepolizumab therapies.This article is protected by copyright. All rights reserved

Source: International Forum of Allergy and Rhinology - August 18, 2022 Category: Allergy & Immunology Authors: Amar Miglani, Zachary M. Soler, Timothy L. Smith, Jess C Mace, Rodney J. Schlosser Tags: ORIGINAL ARTICLE Source Type: research